UPCOMING INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AKRO

Core Viewpoint - Akero Therapeutics, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims centered around misleading statements regarding its clinical trials for the treatment of nonalcoholic steatohepatitis (NASH) [1][3][4]. Company Overview - Akero Therapeutics is a clinical stage biopharmaceutical company focused on developing efruxifermin (EFX) as a treatment for NASH, a serious liver disease [2]. Allegations of the Lawsuit - The lawsuit alleges that Akero made false or misleading statements and failed to disclose critical information during the class period, including: - Approximately 20% of patients in the SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline [3]. - The inclusion of these patients materially influenced the study's potential results and increased the risk of failing to meet primary endpoints [3]. - The study did not align with FDA guidance for testing drugs in NASH cirrhotics, as potential causes of cirrhosis other than NASH were not ruled out [3]. Impact on Stock Price - Following the disclosure of the study's 36-week results on October 10, 2023, Akero's stock price plummeted nearly 70%, leading to substantial losses for investors [4]. Legal Process - Investors who purchased Akero common stock during the class period have until June 25, 2024, to seek appointment as lead plaintiff in the class action lawsuit [1][5]. Firm Background - Robbins Geller Rudman & Dowd LLP is a leading firm in prosecuting investor class actions, having recovered over $1.75 billion for investors in 2022 alone [6][7].